^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
WVT078
i
Other names: WVT078, WVT-078, WVT 078
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Novartis
Drug class:
CD3 agonist, BCMA inhibitor
Related drugs:
2ms
A Study of WVT078 in Patients With Multiple Myeloma (MM) (clinicaltrials.gov)
P1, N=56, Terminated, Novartis Pharmaceuticals | Active, not recruiting --> Terminated; The decision was made for business reasons and was not based on any safety or tolerability concerns
Trial termination
|
WVT078
over1year
A Study of WVT078 in Patients With Multiple Myeloma (MM) (clinicaltrials.gov)
P1, N=56, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Jan 2024 --> Sep 2024 | Trial primary completion date: Jan 2024 --> Sep 2024
Trial completion date • Trial primary completion date
|
WVT078
almost2years
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody. (PubMed, Leukemia)
20 patients (60.6%) experienced cytokine release syndrome. WVT078 has an acceptable safety profile and shows preliminary evidence of clinical activity at doses tested to date.
Clinical data • Preclinical • Journal • IO biomarker
|
WVT078
almost3years
PRECLINICAL DISCOVERY AND EARLY FINDINGS FROM THE PHASE 1, DOSE-ESCALATION STUDY OF WVT078, A BCMA-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH R/R MULTIPLE MYELOMA (EHA 2022)
In the phase 1 study, WVT078 exhibited an acceptable safety profile and preliminary evidence of clinical activity. Clinical evaluation of WVT078 as a single agent and in combination with a gamma secretase inhibitor is ongoing.
P1 data • Preclinical • IO biomarker
|
TNFA (Tumor Necrosis Factor-Alpha)
|
WVT078
Share via
